Drugs / AProArt-CD34
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03538899 | May 2018 → Jun 2038 expected | severe combined immunodeficiency | University of California, San Francisco | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AProArt-CD34 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03538899 ↗ |
| Known as | AProArt | “Participants will undergo infusion with autologous hematopoietic cells transduced with a lentiviral vector, AProArt, which contains the correct form of DCLRE1C complementary...” NCT03538899 ↗ |